Triple-negative breast cancers (TNBCs) are defined as tumors that are negative for estrogen, progesterone and HER-2 receptor. At a percentage of 10-20% TNBCs represent a minority in all breast cancers. However, because of the poor prognosis this particular subtype, triple negative disease accounts for a disproportionate number of metastatic cases and breast cancer deaths. Identification of its subtypes is essential for understanding the biological characteristics and clinical behavior of TNBC, as well as for developing personalized treatments. This review will focus on the great progress that has been made in the past few years on identifying new targets in TNBC subtypes and a variety of new treatment options that are on the verge of routine clinical application.

Keywords:
Triple-negative, Breast cancer, Subtypes, Biological activity
1.
Gnant M, Thomssen C, Harbeck N: St. Gallen/Vienna 2015: a brief summary of the consensus discussion. Breast Care (Basel) 2015;10:124-130.
2.
Denduluri N, Somerfield MR, Eisen A, et al.: Selection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2)-negative and adjuvant targeted therapy for HER2-positive breast cancers: an American Society of Clinical Oncology guideline adaptation of the Cancer Care Ontario Clinical Practice Guideline. J Clin Oncol 2016;34:2416-2427.
3.
Wolff AC, Hammond MEH, Schwartz JN, et al.: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-43.
4.
Rakha EA, El-Sayed ME, Green AR, et al.: Prognostic markers in triple-negative breast cancer. Cancer 2007;109:25-32.
5.
Perou CM, Sørlie T, Eisen MB, et al.: Molecular portraits of human breast tumours. Nature 2000;406:747-752.
6.
Perou CM: Molecular stratification of triple-negative breast cancers. Oncologist 2011;16(suppl 1):61-70.
7.
Cancer Genome Atlas Network: Comprehensive molecular portraits of human breast tumours. Nature 2012;490:61-70.
8.
Andre F, Job B, Dessen P, et al.: Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 2009;15:441-451.
9.
Gewinner C, Wang ZC, Richardson A, et al.: Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 2009;16:115-125.
10.
Saal LH, Holm K, Maurer M, et al.: PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 2005;65:2554-2559.
11.
Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA: Subtyping of triple-negative breast cancer: implications for therapy. Cancer 2015;121:8-16.
12.
Shah SP, Roth A, Goya R, et al.: The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012;486:395-399.
13.
Matros E, Wang ZC, Lodeiro G, et al.: BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat 2005;91:179-186.
14.
Turner N, Tutt A, Ashworth A: Hallmarks of ‘BRCAness' in sporadic cancers. Nat Rev Cancer 2004;4:814-819.
15.
Esteller M, Silva JM, Dominguez G, et al.: Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 2000;92:564-569.
16.
Wei M, Grushko TA, Dignam J, et al.: BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res 2005;65:10692-10699.
17.
Weigman VJ, Chao H-H, Shabalin AA, et al.: Basal-like breast cancer DNA copy number losses identify genes involved in genomic instability, response to therapy, and patient survival. Breast Cancer Res Treat 2012;133:865-880.
18.
Vollebergh MA, Lips EH, Nederlof PM, et al.: An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. Ann Oncol 2011;22:1561-1570.
19.
Cerrato A, Morra F, Celetti A: Use of poly ADP-ribose polymerase (PARP) inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. J Exp Clin Cancer Res 2016;35:179.
20.
Muvarak NE, Chowdhury K, Xia L, et al.: Enhancing the cytotoxic effects of PARP inhibitors with DNA demethylating agents - a potential therapy for cancer. Cancer Cell 2016;30:637-650.
21.
Ohtani H, Mori-Shiraishi K, Nakajima M, Ueki H: Defining lymphocyte-predominant breast cancer by the proportion of lymphocyte-rich stroma and its significance in routine histopathological diagnosis. Pathol Int 2015;65:644-651.
22.
Stanton SE, Adams S, Disis ML: Variation in the incidence and magnitude of tumor-infiltrating lymphocytes in breast cancer subtypes: a systematic review. JAMA Oncol 2016;2:1354-1360.
23.
Mao Y, Qu Q, Chen X, et al.: The prognostic value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis. PLoS ONE 2016;11:e0152500.
24.
García-Martínez E, Gil GL, Benito AC, et al.: Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer. Breast Cancer Res 2014;16:488.
25.
García-Teijido P, Cabal ML, Fernández IP, Pérez YF: Tumor-infiltrating lymphocytes in triple negative breast cancer: the future of immune targeting. Clin Med Insights Oncol 2016;10:31-39.
26.
Lehmann BD, Pietenpol JA: Identification and use of biomarkers in treatment strategies for triple negative breast cancer subtypes. J Pathol 2014;232:142-150.
27.
Lehmann BD, Bauer JA, Chen X, et al.: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750-2767.
28.
Masuda H, Baggerly KA, Wang Y, et al.: Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res 2013;19:5533-5540.
29.
Burstein MD, Tsimelzon A, Poage GM, et al.: Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res 2015;21:1688-1698.
30.
Lehmann BD, Jovanović B, Chen X, et al.: Refinement of triple-negative breast cancer molecular subtypes: implications for neoadjuvant chemotherapy selection. PLoS ONE 2016;11:e0157368.
31.
Ring BZ, Hout DR, Morris SW, et al.: Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. BMC Cancer 2016;16:143.
32.
Stefansson OA, Jonasson JG, Johannsson OT, et al.: Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes. Breast Cancer Res 2009;11:R47.
33.
Telli ML, Timms KM, Reid J, et al.: Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res 2016;22:3764-3773.
34.
Von Minckwitz G, Schneeweiss A, Loibl S, et al.: Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol 2014;15:747-756.
35.
Tutt A, Robson M, Garber JE, et al.: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376:235-244.
36.
Kaufman B, Shapira-Frommer R, Schmutzler RK, et al.: Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015;33:244-250.
37.
Palma JP, Wang Y-C, Rodriguez LE, et al.: ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors. Clin Cancer Res 2009;15:7277-7290.
38.
Isakoff SJ, Overmoyer B, Tung NM, et al.: A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J Clin Oncol 2010;28(suppl):abstr 1019; meetinglibrary.asco.org/content/43191-74.
39.
Rugo HS, Olopade OI, DeMichele A, et al.: Adaptive randomization of veliparib-carboplatin treatment in breast cancer. N Engl J Med 2016;375:23-34.
40.
Drew Y, Ledermann J, Hall G, et al.: Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer 2016;114:723-730.
41.
Niemeier LA, Dabbs DJ, Beriwal S, et al.: Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol 2010;23:205-212.
42.
Pristauz G, Petru E, Stacher E, et al.: Androgen receptor expression in breast cancer patients tested for BRCA1 and BRCA2 mutations. Histopathology 2010;57:877-884.
43.
Gucalp A, Tolaney S, Isakoff SJ, et al.: Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res 2013;19:5505-5512.
44.
Traina TA, Miller K, Yardley DA, et al.: Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC). J Clin Oncol 2015;33 (suppl):abstr 1003; meetinglibrary.asco.org/content/ 150040-156.
45.
Topalian SL, Hodi FS, Brahmer JR, et al.: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-2454.
46.
Mittendorf EA, Philips AV, Meric-Bernstam F, et al.: PD-L1 Expression in triple-negative breast cancer. Cancer Immunol Res 2014;2:361-370.
47.
Schalper KA, Velcheti V, Carvajal D, et al.: In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res 2014;20:2773-2782.
48.
Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-264.
49.
Sharma P, Allison JP: The future of immune checkpoint therapy. Science 2015;348:56-61.
50.
Emens LA, Braiteh FS, Cassier P, et al.: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer. Cancer Res 2015;75(suppl):PD1-6.
51.
Nanda R, Chow LQM, Dees EC, et al.: Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol 2016;34:2460-2467.
52.
Adams S, Diamond JR, Hamilton EP, et al.: Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC). J Clin Oncol 2016;34(suppl):abstr 1009; meetinglibrary.asco.org/content/169304-176.
53.
Vonderheide RH, LoRusso PM, Khalil M, et al.: Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells. Clin Cancer Res 2010;16:3485-3494.
© 2017 S. Karger GmbH, Freiburg
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.